FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Xiuning Le, Jie Wang, Shirish M. Gadgeel et al.|Journal of Clinical Oncology|2024Cited by 5